Biovitrum Starts Collaboration With Karolinska Institutet

Biovitrum AB and Karolinska Institutet (KI) have signed an agreement implicating that Biovitrum Biopharmaceuticals on behalf of the Department of Woman and Child Health shall produce a protein for preclinical research. The production technique to be used has been developed by scientists from KI whereas the actual production will take place at Biovitrum. The protein that the agreement applies to, recombinant HMGB-1 (High Mobility Group Box chromosomal protein 1) is a cytokine like protein, with a significant role in inflammatory reactions.

()a href="http://www.primezone.com/newsroom/?d=79096" target="_blank">PrimeZone